Status:
RECRUITING
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborating Sponsors:
Fudan University
Qilu Hospital of Shandong University
Conditions:
Prostate Cancer Patients
Eligibility:
MALE
40-75 years
Phase:
PHASE1
Brief Summary
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatme...
Detailed Description
Prostate cancer is the development of neoplasia in the prostate, a major gland in the male reproductive system. While most prostate cancers grow slowly, some can develop relatively quickly and aggress...
Eligibility Criteria
Inclusion
- 40 ≤ age ≤ 75 years with histologically proven PCa
- no severe major organ dysfunction
- WHO performance status of 0 or 1
- no prior cancer chemotherapy
- A Clinical Stage ≥ T2c (T2c, N0, M0) of prostate cancer but ideally without diagnosed distant metastasis (according to the 2016 American Joint Committee on Cancer (AJCC) definition of TNM staging system, Staging Manual, Eighth Edition) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan.
Exclusion
- age ≥ 76
- severe major organ dysfunction
- WHO performance status of \>1
- prior cancer chemotherapy
- Stage IV.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03258320
Start Date
January 1 2015
End Date
December 1 2027
Last Update
January 5 2026
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital of Shandong University
Qingdao, Shandong, China, 266035
2
Zhongshan Hospital
Shanghai, China, 200032